Abstract:The coronavirus disease 2019 pandemic has caused more than 532 million infections and 6.3 million deaths to date. The reactive and neutralizing fully human antibodies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective detection tools and therapeutic measures. During SARS-CoV-2 infection, a large number of SARS-CoV-2 reactive and neutralizing antibodies will be produced. Most SARS-CoV-2 reactive and neutralizing fully human antibodies are isolated from human and frequently encoded by convergent heavy-chain variable genes. However, SARS-CoV-2 viruses can mutate rapidly during replication and the resistant variants of neutralizing antibodies easily survive and evade the immune response, especially in the face of such focused antibody responses in humans. Therefore, additional tools are needed to develop different kinds of fully human antibodies to compensate for current deficiency. In this study, we utilized antibody humanized CAMouse HG mice to develop a rapid antibody discovery method and examine the antibody repertoire of SARS-CoV-2 RBD-reactive hybridoma cells derived from CAMouse HG mice by using high-throughput single-cell V(D)J sequencing analysis. CAMouse HG mice were immunized by 28-day rapid immunization method. After electrofusion and semi-solid medium screening on day 12 post-electrofusion, 171 hybridoma clones were generated based on the results of SARS-CoV-2 RBD binding activity assay. A rather obvious preferential usage of IGHV6-1 family was found in these hybridoma clones derived from CAMouse HG mice, which was significantly different from the antibodies found in patients with COVID-19. After further virus neutralization screening and antibody competition assays, we generated a noncompeting two-antibody cocktail, which showed a potent prophylactic protective efficacy against SARS-CoV-2 in cynomolgus macaques. These results indicate that humanized CAMouse HG mice not only provide a valuable platform to obtain fully human reactive and neutralizing antibodies but also have a different antibody repertoire from humans. Thus, humanized CAMouse HG mice can be used as a good complementary tool in discovery of fully human therapeutic and diagnostic antibodies.

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing

Potently neutralizing and protective human antibodies against SARS-CoV-2

Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS‐CoV‐2

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

Monospecific and Bispecific Monoclonal SARS-CoV-2 Neutralizing Antibodies That Maintain Potency Against B.1.617

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Development of Neutralizing Antibodies Against SARS-CoV-2, Using a High-Throughput Single-B-cell Cloning Method

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes